Nebivololo Teva Italia (Nebivolol Hydrochloride)

Nebivolol Hydrochloride, the active ingredient in Nebivololo Teva Italia, is a selective β1‑adrenergic receptor antagonist presented as a tablet for oral use. It is employed to lower high blood pressure and to improve outcomes in patients with heart failure.

GNH USA supplies Nebivololo Teva Italia as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand. Clients benefit from reliable logistics, comprehensive documentation, and responsive technical support throughout the procurement process.

Nebivolol is indicated for cardiovascular conditions that involve elevated blood pressure or impaired cardiac function. - Hypertension: reduces systolic and diastolic blood pressure, helping patients reach target levels. - Heart failure: improves left ventricular ejection fraction and lowers the risk of hospitalization in patients with reduced ejection fraction. - Patients requiring a β‑blocker with vasodilating properties: provides blood‑pressure control while enhancing peripheral vessel relaxation.

Nebivolol may be associated with a range of adverse reactions, which are generally classified by frequency and severity.

Common Side Effects: - Headache: mild to moderate headache reported. - Dizziness: sensation of light‑headedness, especially on standing. - Fatigue: feeling of tiredness or reduced energy. - Nasal congestion: blockage or runny nose. - Bradycardia: slower than normal heart rate. - Gastrointestinal discomfort: nausea or abdominal pain.

Serious or Rare Side Effects: - Severe bradycardia: markedly low heart rate requiring medical attention. - Heart block: atrioventricular conduction disturbances. - Acute heart‑failure decompensation. - Bronchospasm: airway constriction, particularly in patients with asthma. - Hypotension: dangerously low blood pressure. - Allergic reactions: rash, swelling, or anaphylaxis.

When prescribing nebivolol, clinicians should consider several safety considerations and patient‑specific factors. - Cardiovascular assessment: evaluate heart rate and blood pressure before initiation. - Asthma or COPD: use cautiously as β‑blockade may exacerbate bronchospasm. - Diabetes mellitus: monitor glucose control, as β‑blockers can mask hypoglycaemia symptoms. - Liver impairment: dose may need adjustment in moderate to severe hepatic dysfunction. - Drug discontinuation: taper gradually to avoid rebound hypertension or tachycardia. - Store at ambient temperature: keep below 25 °C, in the original container, protected from moisture and light.

Nebivolol can interact with other medicines, altering its effectiveness or increasing the risk of adverse events.

Major Interactions (Avoid): - Non‑selective β‑blockers: concurrent use may cause excessive β‑blockade. - Calcium channel blockers (verapamil, diltiazem): can increase nebivolol plasma levels and bradycardia risk. - CYP2D6 inhibitors (paroxetine, fluoxetine): may raise nebivolol concentrations, leading to heightened effects.

Moderate Interactions (Monitor Closely): - Antihypertensives (ACE inhibitors, diuretics): additive blood‑pressure lowering effect. - Antidiabetic agents (insulin, sulfonylureas): may mask hypoglycaemia symptoms. - NSAIDs (ibuprofen, naproxen): can reduce antihypertensive efficacy. - Digoxin: may increase risk of bradyarrhythmias.